(MedPage Today) — CHICAGO — Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found.
In REDEFINE 1, which included 3,417…
Source link : https://www.medpagetoday.com/meetingcoverage/ada/116188
Author :
Publish date : 2025-06-22 19:09:00
Copyright for syndicated content belongs to the linked Source.
